Evidence map›Paper›PMID 30389997›Full record

ArticleScientific reports2018

An immune cell spray (ICS) formulation allows for the delivery of functional monocyte/macrophages.

Valerie Beneke, Fennja Küster, Anna-Lena Neehus, Christina Hesse, Elena Lopez-Rodriguez, Kathrin Haake, Anna Rafiei Hashtchin, Juliane Wilhelmine Schott, Dorothee Walter, Armin Braun and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valerie BenekeInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Fennja KüsterInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Anna-Lena NeehusInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Christina HesseREBIRTH Cluster of Excellence, Hannover, Germany.
Elena Lopez-RodriguezREBIRTH Cluster of Excellence, Hannover, Germany.
Kathrin HaakeInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Anna Rafiei HashtchinInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Juliane Wilhelmine SchottInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Dorothee WalterREBIRTH Cluster of Excellence, Hannover, Germany.
Armin BraunREBIRTH Cluster of Excellence, Hannover, Germany.
Willem F WolkersREBIRTH Cluster of Excellence, Hannover, Germany.ORCID http://orcid.org/0000-0002-7406-4651
Mania AckermannInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Nico LachmannInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany. lachmann.nico@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages are key cells of the innate immune system and act as tissue resident macrophages (TRMs) in the homeostasis of various tissues. Given their unique functions and therapeutic use as well as the feasibility to derive macrophages in vitro from hematopoietic stem cell (HSC) sources, we propose an "easy-to-use" immune cell spray (ICS) formulation to effectively deliver HSC-derived macrophages. To achieve this aim, we used classical pump spray devices to spray either the human myeloid cell line U937 or primary murine HSC-derived macrophages. For both cell types used, one puff could deliver cells with maintained morphology and functionality. Of note, cells tolerated the spraying process very well with a recovery of more than 90%. In addition, we used osmotic preconditioning to reduce the overall cell size of macrophages. While a 800 mosm hyperosmolar sucrose solution was able to reduce the cell size by 27%, we identified 600 mosm to be effective to reduce the cell size by 15% while maintaining macrophage morphology and functionality. Using an isolated perfused rat lung preparation, the combinatorial use of the ICS with preconditioned and genetically labeled U937 cells allowed the intra-pulmonary delivery of cells, thus paving the way for a new cell delivery platform.

Indexed as

AnimalsCell- and Tissue-Based TherapyCell DifferentiationFeasibility StudiesHematopoietic Stem CellsHumansK562 CellsLungMacrophagesMiceMonocytesOsmosisPerfusionPrimary Cell CultureRatsU937 Cells

Identifiers

PMID30389997
PMCPMC6214992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.